Research programme: diabetic complications therapeutics - Cengent Therapeutics/Dynamis Therapeutics
Latest Information Update: 31 Aug 2007
At a glance
- Originator Cengent Therapeutics; Dynamis Therapeutics
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetic complications
Most Recent Events
- 31 Aug 2007 No development reported for Diabetic complications in USA (unspecified route)
- 19 Aug 2005 This programme is still in active development (BIO-2005)
- 18 Nov 2004 Early research in Diabetic complications in USA (unspecified route)